替沙仑赛治疗原发性中枢神经系统淋巴瘤的安全性与疗效:一项1/2期临床试验
这项1/2期临床试验评估了替沙仑赛在12例高度难治性复发性原发性中枢神经系统淋巴瘤(PCNSL)患者中的安全性和疗效,中位随访12.2个月。7/12例(58.3%)出现1级细胞因子释放综合征,5/12例(41.6%)出现低级别ICANS,仅1例发生3级ICANS。7/12例(58.3%)获得缓解,其中6/12例(50%)完全缓解,无治疗相关死亡。
要点
- 12例复发性PCNSL患者接受替沙仑赛,中位随访12.2个月(范围3.64-23.5)。
- 7/12例(58.3%)出现1级细胞因子释放综合征,5/12例(41.6%)出现低级别ICANS,仅1例发生3级ICANS。
- 7/12例(58.3%)获得缓解,其中6/12例(50%)完全缓解,3例在数据截止时持续完全缓解。
核心结论
- 替沙仑赛在这组高度难治性PCNSL患者中耐受性良好,7例初始缓解者中3例(42.9%)获得持续缓解。
- 这些数据提示替沙仑赛在该高度难治性患者人群中安全有效。
研究设计与样本
- 1/2期临床试验,纳入12例复发性原发性中枢神经系统淋巴瘤(PCNSL)患者,接受替沙仑赛治疗。
- 中位随访时间为12.2个月(范围3.64-23.5个月)。
- 试验注册号为NCT02445248。
主要发现
- 1级细胞因子释放综合征见于7/12例患者(58.3%)。
- 低级别ICANS见于5/12例患者(41.6%),仅1例患者发生3级ICANS。
- 7/12例患者(58.3%)获得缓解,其中6/12例(50%)为完全缓解。
- 无治疗相关死亡;数据截止时3例患者持续完全缓解。
- 替沙仑赛在外周血中扩增并迁移至中枢神经系统;与基线相比,输注后脑脊液中可检测到T细胞、CAR-T和巨噬细胞基因特征。
关键数值与推荐
- 缓解定义为7/12例(58.3%)获得缓解,其中完全缓解6/12例(50%)。
- 初始缓解者中持续缓解比例为3/7(42.9%)。
- 细胞因子释放综合征1级7/12例(58.3%);ICANS低级别5/12例(41.6%),3级1例。
临床怎么用
- 原文未据此给出推荐。
- 作者认为替沙仑赛在该高度难治性PCNSL患者人群中安全有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed chimerical antigen receptor T-cell (CAR-T) products have gained US Food and Drug Administration approval for systemic large B-cell lymphoma. Because of concerns about potential immune cell-associated neurotoxicity syndrome (ICANS), patients with primary central nervous system (CNS) lymphoma (PCNSL) were excluded from all pivotal CAR-T studies. We conducted a phase 1/2 clinical trial of tisagenlecleucel in a highly refractory patients with PCNSL and significant unmet medical need. Here, we present results of 12 relapsed patients with PCNSL who were treated with tisagenlecleucel and followed for a median time of 12.2 months (range, 3.64-23.5). Grade 1 cytokine release syndrome was observed in 7/12 patients (58.3%), low-grade ICANS in 5/12 (41.6%) patients, and only 1 patient experienced grade 3 ICANS. Seven of 12 patients (58.3%) demonstrated response, including a complete response in 6/12 patients (50%). There were no treatment-related deaths. Three patients had ongoing complete remission at data cutoff. Tisagenlecleucel expanded in the peripheral blood and trafficked to the CNS. Exploratory analysis identified T-cell, CAR T, and macrophage gene signatures in cerebrospinal fluid following infusion when compared with baseline. Overall, tisagenlecleucel was well tolerated and resulted in a sustained remission in 3/7 (42.9%) of initial responders. These data suggest that tisagenlecleucel is safe and effective in this highly refractory patient population. This trial was registered at www.clinicaltrials.gov as #NCT02445248.
引用
- Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022. PMID: 35167655. doi:10.1182/blood.2021014738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。